A Pig Kidney Bridged One Patient to Human Transplant
A gene-edited pig kidney kept one patient off dialysis for 271 days before microvascular injury caused graft failure; the patient later received a human kidney without detected sensitisation.
The 60-second version
A gene-edited pig kidney provided one patient 271 dialysis-free days and did not prevent a later human-kidney transplant, but the xenograft ultimately failed from microvascular injury.
Key points
- An early T-cell-mediated rejection episode on day 14 resolved with treatment.
- After immunosuppression was reduced during a non-zoonotic bacterial infection, endothelial injury progressed to thrombotic microangiopathy.
- No porcine pathogen transmission or change in anti-HLA antibodies was detected in this case.
- A human kidney was transplanted 82 days after explantation and showed immediate function, with no sensitisation detected through 231 days.
Verdict. The case establishes feasibility for a bridge strategy in one person; it does not establish long-term safety, superiority to dialysis or readiness for routine care.
A gene-edited pig kidney kept one patient with end-stage kidney disease off dialysis for 271 days. The graft ultimately failed after progressive injury to its smallest blood vessels, but the patient later received a human kidney without detected immune sensitisation.
The caseThe graft provided nine months without dialysis
The patient had end-stage kidney disease, no suitable living donor and a long expected wait for a deceased-donor organ. On Jan 25, 2025, clinicians at Massachusetts General Hospital transplanted a gene-edited pig kidney under an FDA Expanded Access Investigational New Drug application.
| Donor kidney | EGEN-2784, with major glycan xenoantigens deleted, porcine endogenous retroviruses inactivated and seven human transgenes inserted. |
|---|---|
| Immune control | Costimulation blockade-based immunosuppression plus complement inhibition. |
| Study design | First recipient in a planned three-patient study. |
| Primary scope | A case report assessing graft durability, infection surveillance and whether a later human transplant remained possible. |
The kidney worked immediately. A biopsy on day 14 showed T-cell-mediated rejection, which resolved with treatment. Graft function then remained stable for about six months.
Graft failureLate injury centred on the microvasculature
During a bacterial infection that was not traced to the pig, clinicians reduced immunosuppression. Microvascular inflammation and endothelial injury then emerged and progressed to thrombotic microangiopathy, prompting removal of the failed graft.
The late tissue pattern differed from the early rejection episode. Macrophages and natural killer cells predominated, T-cell involvement was minimal, and donor-specific crossmatch testing remained negative. The authors suggest that mechanisms beyond conventional antibody-mediated rejection may have contributed.
The 271-day result demonstrates prolonged support, but the late vascular failure identifies the problem future trials must solve.
The bridgeA later human transplant remained possible
Monitoring found no porcine pathogen transmission, and anti-HLA antibody levels remained unchanged. Eighty-two days after the pig kidney was removed, the patient received a human kidney with immediate function. The report found no evidence of sensitisation during 231 days of follow-up.
These observations address two major bridge-strategy concerns: infection crossing from donor species and an immune response that might block a later human organ. Neither problem was detected here, but one negative case cannot establish population-level safety.
Evidence boundaryFeasibility is not yet comparative benefit
- 1. One patient: the report cannot estimate how often graft failure, infection or sensitisation will occur.
- 2. No comparison group: it does not show that a pig-kidney bridge is safer than remaining on dialysis or improves survival.
- 3. Unresolved mechanism: infection, immunosuppression reduction, innate immune activity, endothelial injury and coagulation may all matter.
- 4. Limited follow-up: 231 days after human transplantation is reassuring but not a long-term outcome.
- 5. Funding context: Massachusetts General Hospital and eGenesis funded the study; eGenesis is associated with the donor organ.
The next studies need to prevent microvascular injury, define the roles of macrophages and natural killer cells, and test how immunosuppression can be adjusted safely during infection. For now, the case supports bridge-to-human-transplantation as a research strategy, not standard care.